Trending News
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- This event has passed.
12th Annual Inflammatory Bowel Disease: The Art and Science in the Diagnosis and Treatment in 2019
September 13, 2019 - September 14, 2019
This meeting will enable participants to enhance their knowledge, competency and performance in the areas of patient care and practice-based improvement in the diagnosis and management of patients with Crohn disease (CD) and ulcerative colitis (UC) so as to improve quality of life of these patients while prolonging clinical remission.
12.5 AMA PRA Category 1 Credits™
12.5 ABIM MOC points